Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis

International Journal of Antimicrobial Agents

Volumn 48, Issue 1, 2016, Pages 1-10

  Vardakas, Konstantinos Z ^a,b   Trigkidis, Kyriakos K ^a   Boukouvala, Eleni ^c   Falagas, Matthew E ^a,b,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Clostridium difficile; Colitis; Diarrhoea

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; LINEZOLID; PENICILLIN DERIVATIVE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; META ANALYSIS; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTION; DIARRHEA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84969570475     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.03.008     Document Type: Review

References (108)

1. [1] US Centers for Disease Control and Prevention, Antibiotic resistance threats in the United States. 2013, CDC, Atlanta, GA.
2. [2] Vardakas, K.Z., Polyzos, K.A., Patouni, K., Rafailidis, P.I., Samonis, G., Falagas, M.E., Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 40 (2012), 1–8.
3. [3] Lessa, F.C., Gould, C.V., McDonald, L.C., Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55:Suppl. 2 (2012), S65–70.
4. [4] Kuntz, J.L., Chrischilles, E.A., Pendergast, J.F., Herwaldt, L.A., Polgreen, P.M., Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case–control study. BMC Infect Dis, 11, 2011, 194.
5. [5] Brown, K.A., Khanafer, N., Daneman, N., Fisman, D.N., Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57 (2013), 2326–2332.
6. [6] Deshpande, A., Pasupuleti, V., Thota, P., Pant, C., Rolston, D.D., Sferra, T.J., et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 68 (2013), 1951–1961.
7. [7] Slimings, C., Riley, T.V., Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69 (2014), 881–891.
8. [8] Thomas, C., Stevenson, M., Riley, T.V., Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 51 (2003), 1339–1350.
9. [9] Pepin, J., Saheb, N., Coulombe, M.A., Alary, M.E., Corriveau, M.P., Authier, S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005), 1254–1260.
10. [10] Vardakas, K.Z., Konstantelias, A.A., Loizidis, G., Rafailidis, P.I., Falagas, M.E., Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis 16 (2012), e768–73.
11. [11] Alveyn, C.G., Robertson, D.A., Wright, R., Lowes, J.A., Tillotson, G., Prevention of sepsis following endoscopic retrograde cholangiopancreatography. J Hosp Infect 19:Suppl. C (1991), 65–70.
12. [12] Anzueto, A., Niederman, M.S., Pearle, J., Restrepo, M.I., Heyder, A., Choudhri, S.H., et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 42 (2006), 73–81.
13. [13] Babinchak, T., Ellis-Grosse, E., Dartois, N., Rose, G.M., Loh, E., et al., Tigecycline 301 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41:Suppl. 5 (2005), S354–67.
14. [14] Bergallo, C., Jasovich, A., Teglia, O., Oliva, M.E., Lentnek, A., de Wouters, L., et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 63 (2009), 52–61.
15. [15] Bodey, G., Abi-Said, D., Rolston, K., Raad, I., Whimbey, E., Imipenem or cefoperazone–sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 15 (1996), 625–634.
16. [16] Bodey, G.P., Fainstein, V., Elting, L.S., Anaissie, E., Rolston, K., Khardori, N., et al. β-Lactam regimens for the febrile neutropenic patient. Cancer 65 (1990), 9–16.
17. [17] Bow, E.J., Rotstein, C., Noskin, G.A., Laverdiere, M., Schwarer, A.P., Segal, B.H., et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin–tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43 (2006), 447–459.
18. [18] Chandrasekar, P.H., Arnow, P.M., Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 34 (2000), 989–995.
19. [19] Chen, A.E., Carroll, K.C., Diener-West, M., Ross, T., Ordun, J., Goldstein, M.A., et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics 127 (2011), e573–80.
20. [20] Cherif, H., Björkholm, M., Engervall, P., Johansson, P., Ljungman, P., Hast, R., et al. A prospective, randomized study comparing cefepime and imipenem–cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 36 (2004), 593–600.
21. [21] Chodosh, S., McCarty, J., Farkas, S., Drehobl, M., Tosiello, R., Shan, M., et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 27 (1998), 722–729.
22. [22] Corapcioglu, F., Sarper, N., Zengin, E., Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol 23 (2006), 177–186.
23. [23] Cordero, E., Bouza, E., Ruiz, I., Pachon, J., Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial. J Antimicrob Chemother 48 (2001), 527–534.
24. [24] Corrêa, J.C., Badaró, R., Bumroongkit, C., Mera, J.R., Dolmann, A.L., Juárez Martínez, L.G., et al. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 25 (2003), 1453–1468.
25. [25] Cronberg, S., Banke, S., Bergman, B., Boman, H., Eilard, T., Elbel, E., et al. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis 33 (2001), 339–343.
26. [26] Dattwyler, R.J., Luft, B.J., Kunkel, M.J., Finkel, M.F., Wormser, G.P., Rush, T.J., et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 337 (1997), 289–294.
27. [27] De Waele, J.J., Tellado, J.M., Alder, J., Reimnitz, P., Jensen, M., Hampel, B., et al. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. Int J Antimicrob Agents 41 (2013), 57–64.
28. [28] Edelstein, H., Chirurgi, V., Oster, S., Karp, R., Cassano, K., Aiken, S., et al. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother 28 (1991), 569–575.
29. [29] Eppes, S.C., Childs, J.A., Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 109 (2002), 1173–1177.
30. [30] Farkas, S.A., Intravenous fleroxacin versus ceftazidime in the treatment of acute nonpneumococcal lower respiratory tract infections. Am J Med, 94, 1993, 142S-9S.
31. [31] Freifeld, A.G., Walsh, T., Marshall, D., Gress, J., Steinberg, S.M., Hathorn, J., et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13 (1995), 165–176.
32. [32] Freire, A.T., Melnyk, V., Kim, M.J., Datsenko, O., Dzyublik, O., Glumcher, F., et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68 (2010), 140–151.
33. [33] Giordano, P., Song, J., Pertel, P., Herrington, J., Kowalsky, S., Sequential intravenous/oral moxifloxacin versus intravenous piperacillin–tazobactam followed by oral amoxicillin–clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 26 (2005), 357–365.
34. [34] Gopal Rao, G., Mahankali Rao, C.S., Starke, I., Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with β-lactam-based therapy. J Antimicrob Chemother 51 (2003), 697–701.
35. [35] Graham, D.R., Lucasti, C., Malafaia, O., Nichols, R.L., Holtom, P., Perez, N.Q., et al. Ertapenem once daily versus piperacillin–tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 34 (2002), 1460–1468.
36. [36] Grayson, M.L., Gibbons, G.W., Habershaw, G.M., Freeman, D.V., Pomposelli, F.B., Rosenblum, B.I., et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 18 (1994), 683–693.
37. [37] Grossman, R.F., Campbell, D.A., Landis, S.J., Garber, G.E., Murray, G., Stiver, H.G., et al. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother 43 (1999), 549–554.
38. [38] Gyssens, I.C., Dryden, M., Kujath, P., Nathwani, D., Schaper, N., Hampel, B., et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 66 (2011), 2632–2642.
39. [39] Hall, J.C., Hall, J.L., Christiansen, K., A comparison of the roles of cefamandole and ceftriaxone in abdominal surgery. Arch Surg 126 (1991), 512–516.
40. [40] Harter, C., Schulze, B., Goldschmidt, H., Benner, A., Geiss, H.K., Hoppe-Tichy, T., et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 37 (2006), 373–379.
41. [41] Hassler, D., Zöller, L., Haude, M., Hufnagel, H.D., Heinrich, F., Sonntag, H.G., Cefotaxime versus penicillin in the late stage of Lyme disease—prospective, randomized therapeutic study. Infection 18 (1990), 16–20.
42. [42] Hirata-Dulas, C.A., Stein, D.J., Guay, D.R., Gruninger, R.P., Peterson, P.K., A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc 39 (1991), 979–985.
43. [43] Holloway, W.J., Palmer, D., Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections. Am J Med, 100, 1996, 52S-9S.
44. [44] Itani, K.M., Wilson, S.E., Awad, S.S., Jensen, E.H., Finn, T.S., Abramson, M.A., Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 355 (2006), 2640–2651.
45. [45] Ito, I., Kadowaki, S., Tanabe, N., Haruna, A., Kase, M., Yasutomo, Y., et al. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin. Pulm Pharmacol Ther 23 (2010), 403–410.
46. [46] Johnson, J.T., Kachman, K., Wagner, R.L., Myers, E.N., Comparison of ampicillin/sulbactam versus clindamycin in the prevention of infection in patients undergoing head and neck surgery. Head Neck 19 (1997), 367–371.
47. [47] Katelaris, P.H., Adamthwaite, D., Midolo, P., Yeomans, N.D., Davidson, G., Lambert, J., Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. Aliment Pharmacol Ther 14 (2000), 751–758.
48. [48] Kusachi, S., Sumiyama, Y., Takahashi, Y., Kato, K., Mashita, K., Takeyama, H., et al. Evaluation of the efficacy and safety of intravenous ciprofloxacin versus meropenem in the treatment of postoperative infection. J Infect Chemother 18 (2012), 152–159.
49. [49] Lipsky, B.A., Pecoraro, R.E., Larson, S.A., Hanley, M.E., Ahroni, J.H., Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 150 (1990), 790–797.
50. [50] Luterman, M., Tellier, G., Lasko, B., Leroy, B., Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 82 (2003), 576–580 582-4, 586 passim.
51. [51] McCabe, R., Chirurgi, V., Farkas, S.A., Haddow, A., Heinz, G., Greene, S., A new therapeutic option for the treatment of pneumonia. Am J Med, 100, 1996, 60S-7S.
52. [52] Nemeth, M.A., McCarty, J., Gooch, W.M. 3rd, Henry, D., Keyserling, C.H., Tack, K.J., Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Clin Ther 21 (1999), 1873–1881.
53. [53] Nichols, R.L., Smith, J.W., Geckler, R.W., Wilson, S.E., Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 88 (1995), 397–404.
54. [54] Raad, I.I., Escalante, C., Hachem, R.Y., Hanna, H.A., Husni, R., Afif, C., et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 98 (2003), 1039–1047.
55. [55] Raad, I.I., Whimbey, E.E., Rolston, K.V., Abi-Said, D., Hachem, R.Y., Pandya, R.G., et al. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 77 (1996), 1386–1394.
56. [56] Rolston, K.V., Berkey, P., Bodey, G.P., Anaissie, E.J., Khardori, N.M., Joshi, J.H., et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152 (1992), 283–291.
57. [57] Rubenstein, E.B., Rolston, K., Benjamin, R.S., Loewy, J., Escalante, C., Manzullo, E., et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71 (1993), 3640–3646.
58. [58] San Pedro, G.S., Cammarata, S.K., Oliphant, T.H., Todisco, T., Linezolid Community-Acquired Pneumonia Study Group. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 34 (2002), 720–728.
59. [59] Sharifi, R., Geckler, R., Childs, S., Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. Am J Med 100 (1996), 76S–82S.
60. [60] Siami, G., Christou, N., Eiseman, I., Tack, K.J., Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin–tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 45 (2001), 525–531.
61. [61] Skitarelić, N., Morović, M., Manestar, D., Antibiotic prophylaxis in clean-contaminated head and neck oncological surgery. J Craniomaxillofac Surg 35 (2007), 15–20.
62. [62] Solomkin, J.S., Wilson, S.E., Christou, N.V., Rotstein, O.D., Dellinger, E.P., Bennion, R.S., et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg 233 (2001), 79–87.
63. [63] Solomkin, J.S., Yellin, A.E., Rotstein, O.D., Christou, N.V., Dellinger, E.P., Tellado, J.M., et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237 (2003), 235–245.
64. [64] Soper, D.E., Brockwell, N.J., Dalton, H.P., The importance of wound infection in antibiotic failures in the therapy of postpartum endometritis. Surg Gynecol Obstet 174 (1992), 265–269.
65. [65] Stiver, H.G., Binns, B.O., Brunham, R.C., Cheng, N., Dean, D.M., Goldring, A.M., et al. Randomized, double-blind comparison of the efficacies, costs, and vaginal flora alterations with single-dose ceftriaxone and multidose cefazolin prophylaxis in vaginal hysterectomy. Antimicrob Agents Chemother 34 (1990), 1194–1197.
66. [66] Tammela, T., Kontturi, M., Usenius, R., Uusi-Penttilä, S., Viitanen, J., Jauhiainen, K., Ceftazidime vs. tobramycin for serious infections in urological patients. J Hosp Infect 15:Suppl. A (1990), 69–76.
67. [67] Tazuma, S., Igarashi, Y., Tsuyuguchi, T., Ohara, H., Inui, K., Ohya, T., et al. Clinical efficacy of intravenous ciprofloxacin in patients with biliary tract infection: a randomized controlled trial with carbapenem as comparator. J Gastroenterol 44 (2009), 781–792.
68. [68] Upchurch, J., Rosemore, M., Tosiello, R., Kowalsky, S., Echols, R., Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg 135 (2006), 511–517.
69. [69] Vetter, N., Cambronero-Hernandez, E., Rohlf, J., Simon, S., Carides, A., Oliveria, T., et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 24 (2002), 1770–1785.
70. [70] von Konow, L., Köndell, P.A., Nord, C.E., Heimdahl, A., Clindamycin versus phenoxymethylpenicillin in the treatment of acute orofacial infections. Eur J Clin Microbiol Infect Dis 11 (1992), 1129–1135.
71. [71] von Mandach, U., Huch, R., Malinverni, R., Huch, A., Ceftriaxone (single dose) versus cefoxitin (multiple doses): success and failure of antibiotic prophylaxis in 1052 cesarean sections. J Perinat Med 21 (1993), 385–397.
72. [72] Wacha, H., Warren, B., Bassaris, H., Nikolaidis, P., Intra-Abdominal Infections Study Group. Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections. Surg Infect (Larchmt) 7 (2006), 341–354.
73. [73] Weber, K., Preac-Mursic, V., Wilske, B., Thurmayr, R., Neubert, U., Scherwitz, C., A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection 18 (1990), 91–96.
74. [74] Wilson, R., Schentag, J.J., Ball, P., Mandell, L., 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 24 (2002), 639–652.
75. [75] Winslet, M.C., Youngs, D., Burdon, D.W., Keighley, M.R., Short-term chemoprophylaxis with ceftizoxime vs. five-day aminoglycoside with metronidazole in ‘contaminated’ lower gastrointestinal surgery. Dis Colon Rectum 33 (1990), 878–882.
76. [76] Winston, D.J., Lazarus, H.M., Beveridge, R.A., Hathorn, J.W., Gucalp, R., Ramphal, R., et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 32 (2001), 381–390.
77. [77] Zanetti, G., Bally, F., Greub, G., Garbino, J., Kinge, T., Lew, D., et al. Cefepime versus imipenem–cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47 (2003), 3442–3447.
78. [78] Zanetti, G., Harbarth, S.J., Trampuz, A., Ganeo, M., Mosimann, F., Chautemps, R., et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents 11 (1999), 107–113.
79. [79] Fanning, J., Sweetland, D.J., Hilgers, R.D., A prospective randomized trial of ampicillin/sulbactam vs cefoxitin prophylaxis for radical gynecologic surgery. Int J Gynecol Cancer 6 (1996), 298–301.
80. [80] Blaszczyk-Kostanecka, M., Dobozy, A., Dominguez-Soto, L., Guerrero, R., Hunyadi, J., Lopera, J., et al. Comparison of two regimens of oral clindamycin versus dicloxacillin in the treatment of mild-to-moderate skin and soft-tissue infections. Curr Ther Res 59 (1998), 341–353.
81. [81] Nicolle, L.E., Kirshen, A., Boustcha, E., Montgomery, P., Treatment to moderate-to-severe pneumonia in elderly, long-term care facility residents. Infect Dis Clin Pract (Baltim Md) 5 (1996), 130–137.
82. [82] Snedden, S., Rudoy, R., Arrieta, A., Blummer, J., Meropenem versus cefotaxime-based therapy for the initial treatment of infants and children hospitalised with non-CNS infections. Clin Drug Investig 17 (1999), 9–20.
83. [83] Rubinstein, E., Cammarata, S., Oliphant, T., Wunderink, R., Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32 (2001), 402–412.
84. [84] Kureishi, A., Jewesson, P.J., Rubinger, M., Cole, C.D., Reece, D.E., Phillips, G.L., et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 35 (1991), 2246–2252.
85. [85] Stevens, D.L., Herr, D., Lampiris, H., Hunt, J.L., Batts, D.H., Hafkin, B., Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34 (2002), 1481–1490.
86. [86] Cepeda, J.A., Whitehouse, T., Cooper, B., Hails, J., Jones, K., Kwaku, F., et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 53 (2004), 345–355.
87. [87] Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., Knirsch, C., et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005), 2260–2266.
88. [88] Wilcox, M.H., Tack, K.J., Bouza, E., Herr, D.L., Ruf, B.R., Ijzerman, M.M., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48 (2009), 203–212.
89. [89] Wunderink, R.G., Niederman, M.S., Kollef, M.H., Shorr, A.F., Kunkel, M.J., Baruch, A., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54 (2012), 621–629.
90. [90] Paul, M., Yahav, D., Bivas, A., Fraser, A., Leibovici, L., Anti-pseudomonal β-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of β-lactams. Cochrane Database Syst Rev(11), 2010 CD005197.
91. [91] Shiber, S., Yahav, D., Avni, T., Leibovici, L., Paul, M., β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 70 (2015), 41–47.
92. [92] Hecht, D.W., Galang, M.A., Sambol, S.P., Osmolski, J.R., Johnson, S., Gerding, D.N., In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 51 (2007), 2716–2719.
93. [93] Nagy, E., Dowzicky, M.J., In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 42 (2010), 33–38.
94. [94] Peláez, T., Alcalá, L., Blanco, J.L., Álvarez-Pérez, S., Marín, M., Martín-López, A., et al. Characterization of swine isolates of Clostridium difficile in Spain: a potential source of epidemic multidrug resistant strains?. Anaerobe 22 (2013), 45–49.
95. [95] Kager, L., Brismar, B., Malmborg, A.S., Nord, C.E., Imipenem concentrations in colorectal surgery and impact on the colonic microflora. Antimicrob Agents Chemother 33 (1989), 204–208.
96. [96] Condon, R.E., Walker, A.P., Hanna, C.B., Greenberg, R.N., Broom, A., Pitkin, D., Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Clin Infect Dis 24:Suppl. 2 (1997), S181–3.
97. [97] Pletz, M.W., Rau, M., Bulitta, J., De Roux, A., Burkhardt, O., Kruse, G., et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 48 (2004), 3765–3772.
98. 14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother 52 (2008), 3478–3483.
99. [99] Bergan, T., Nord, C.E., Thorsteinsson, S.B., Effect of meropenem on the intestinal microflora. Eur J Clin Microbiol Infect Dis 10 (1991), 524–527.
100. [100] Nord, C.E., Kager, L., Philipson, A., Stiernstedt, G., Effect of imipenem/cilastatin on the colonic microflora. Rev Infect Dis 7:Suppl. 3 (1985), S432–4.
101. [101] Brismar, B., Edlund, C., Nord, C.E., Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. Eur J Clin Microbiol Infect Dis 12 (1993), 714–719.
102. [102] Privitera, G., Scarpellini, P., Ortisi, G., Nicastro, G., Nicolin, R., de Lalla, F., Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 35 (1991), 208–210.
103. [103] Hung, Y.P., Tsai, P.J., Hung, K.H., Liu, H.C., Lee, C.I., Lin, H.J., et al. Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS ONE, 7, 2012, e42415.
104. [104] Owens, R.C. Jr, Donskey, C.J., Gaynes, R.P., Loo, V.G., Muto, C.A., Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46:Suppl. 1 (2008), S19–31.
105. [105] Dial, S., Kezouh, A., Dascal, A., Barkun, A., Suissa, S., Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 179 (2008), 767–772.
106. [106] Hensgens, M.P., Goorhuis, A., Dekkers, O.M., Kuijper, E.J., Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 67 (2012), 742–748.
107. [107] Evans, C.T., Safdar, N., Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 60:Suppl. 2 (2015), S66–71.
108. [108] Davies, K.A., Longshaw, C.M., Davis, G.L., Bouza, E., Barbut, F., Barna, Z., et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 14 (2014), 1208–1219.